Bristol-Myers Squibb Company (BMY) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Bristol-Myers Squibb Company (BMY) Healthcare & Pipeline Overview

Bristol-Myers Squibb is a global biopharmaceutical company distinguished by its diverse portfolio of innovative medicines, particularly in oncology, hematology, immunology, and cardiovascular diseases. With a strong focus on research and development, BMY operates in a competitive landscape, delivering therapies to wholesalers, distributors, pharmacies, and healthcare providers worldwide.

What Is the Investment Thesis for BMY?

Bristol-Myers Squibb presents a compelling, albeit complex, investment case. With a market capitalization of $134B and a P/E ratio of 15.6, the company demonstrates established profitability, supported by a 15.0% profit margin and a robust 68.7% gross margin. A key value driver is BMY's diverse product portfolio, which mitigates risk across various therapeutic areas. Growth catalysts include the continued expansion of key drugs like Opdivo and Eliquis, as well as the introduction of newer products such as Zeposia and Breyanzi. However, investors may want to evaluate potential risks, including patent expirations for key drugs and the inherent uncertainties of pharmaceutical research and development. The company's dividend yield of 4.45% offers an attractive return for income-seeking investors, but future dividend growth will depend on sustained earnings and cash flow.

Based on FMP financials and quantitative analysis

BMY Key Highlights

Market Cap of $134B indicates a substantial and stable company within the pharmaceutical industry.

• P/E Ratio of 15.6 suggests the company is reasonably valued compared to its earnings.
• Profit Margin of 15.0% demonstrates effective cost management and strong pricing power.
• Gross Margin of 68.7% highlights the high value-added nature of the company's pharmaceutical products.
• Dividend Yield of 4.45% provides an attractive income stream for investors, reflecting the company's commitment to shareholder returns.

Who Are BMY's Competitors?

BMY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are BMY's Key Strengths?

Diverse product portfolio across multiple therapeutic areas.

• Strong research and development capabilities.
• Global presence and established distribution network.
• Robust patent protection for key products.

What Are BMY's Weaknesses?

Reliance on key products with potential patent expirations.

• Exposure to regulatory and pricing pressures.
• High research and development costs.
• Competition from generic drug manufacturers.

What Could Drive BMY Stock Higher?

Clinical trial results for key pipeline drugs in oncology and immunology by Q4 2026.

• Continued expansion of Opdivo and Eliquis into new indications.
• Strategic acquisitions and partnerships to expand product portfolio.

What Are the Key Risks for BMY?

Insider selling — insiders were net sellers of roughly $2.0M recently.

• Patent expirations for key products, leading to generic competition.
• Regulatory changes and pricing pressures impacting profitability.
• Clinical trial failures for pipeline drugs.
• Competition from other pharmaceutical companies.
• Product liability lawsuits and other legal challenges.

What Are the Growth Opportunities for BMY?

• Expansion of Oncology Portfolio: Bristol-Myers Squibb has significant growth potential in the oncology market, driven by its key drug, Opdivo, and newer therapies like Breyanzi. The global oncology market is projected to reach $400 billion by 2030, presenting a substantial opportunity for BMY to increase its market share through continued clinical development and commercialization of innovative cancer treatments. Success in this area will depend on positive clinical trial outcomes and regulatory approvals.
• Growth in Immunology: With products like Orencia and Zeposia, Bristol-Myers Squibb is well-positioned to capitalize on the growing immunology market. The increasing prevalence of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis is driving demand for effective therapies. The global immunology market is expected to reach $150 billion by 2028, offering BMY a significant opportunity to expand its presence through new indications and formulations.
• Cardiovascular Disease Therapies: Eliquis, a leading oral anticoagulant, continues to be a key growth driver for Bristol-Myers Squibb in the cardiovascular market. As the global population ages, the incidence of atrial fibrillation and venous thromboembolism is expected to increase, driving demand for effective anticoagulation therapies. The cardiovascular drug market is projected to reach $200 billion by 2027, providing BMY with continued growth opportunities.
• Emerging Markets Expansion: Bristol-Myers Squibb has the opportunity to expand its presence in emerging markets, where healthcare spending is increasing and access to innovative medicines is improving. Countries like China, India, and Brazil represent significant growth opportunities for BMY's key products. Successful expansion will require strategic partnerships, regulatory approvals, and effective distribution networks. This expansion can contribute significantly to BMY's long-term revenue growth.
• Strategic Acquisitions and Partnerships: Bristol-Myers Squibb can drive growth through strategic acquisitions and partnerships that expand its product portfolio and pipeline. By acquiring or licensing innovative therapies from other companies, BMY can accelerate its growth in key therapeutic areas. The company has a history of successful acquisitions, and continued strategic deal-making will be essential for maintaining its competitive position and driving long-term value creation. These partnerships can provide access to cutting-edge research and development.

What Opportunities Does BMY Have?

• Expansion into emerging markets.
• Development of new therapies for unmet medical needs.
• Strategic acquisitions and partnerships.
• Growth in personalized medicine and targeted therapies.

What Are BMY's Competitive Advantages?

• Patent protection for key pharmaceutical products.
• Strong brand reputation and established relationships with healthcare providers.
• Extensive research and development capabilities.
• Diverse product portfolio across multiple therapeutic areas.

What Does BMY Do?

Founded in 1887, Bristol-Myers Squibb (BMY) has evolved into a leading global biopharmaceutical company dedicated to discovering, developing, licensing, manufacturing, and marketing innovative medicines. The company's origins trace back to two separate entities: the Bristol-Myers Company and E.R. Squibb & Sons, which merged in 1989. BMY's therapeutic focus spans several key areas, including oncology, hematology, immunology, fibrotic diseases, neuroscience, and cardiovascular diseases. Its diverse product portfolio includes notable drugs such as Revlimid, an oral immunomodulatory drug for multiple myeloma; Eliquis, an oral inhibitor used to reduce the risk of stroke; Opdivo, an anti-cancer therapy; and Orencia, for rheumatoid and psoriatic arthritis. Other key products include Sprycel, Yervoy, Abraxane, Reblozyl, Empliciti, Zeposia, Breyanzi, Inrebic, and Onureg. BMY markets its products globally through a network of wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies, solidifying its position in the competitive pharmaceutical market. The company is headquartered in Princeton, New Jersey, and employs over 34,100 individuals worldwide.

What Products and Services Does BMY Offer?

• Discovers novel biopharmaceutical products through research and development.
• Develops and formulates pharmaceutical drugs for various therapeutic areas.
• Licenses pharmaceutical products for commercialization.
• Manufactures biopharmaceutical products on a global scale.
• Markets and sells biopharmaceutical products to healthcare providers and patients.
• Offers therapies for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and COVID-19 diseases.
• Distributes products through wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies.

How Does BMY Make Money?

• Develops and patents innovative pharmaceutical products.
• Generates revenue through the sale of prescription drugs.
• Invests heavily in research and development to discover new therapies.
• Markets and distributes products globally through various channels.

What Industry Does BMY Operate In?

Bristol-Myers Squibb operates within the highly competitive and regulated pharmaceutical industry. The industry is characterized by intense research and development efforts, stringent regulatory requirements, and patent protection. Market trends include a growing demand for innovative therapies, particularly in oncology, immunology, and cardiovascular diseases. The competitive landscape includes major players such as Pfizer Inc. (PFE), Sanofi (SNY), and Vertex Pharmaceuticals Incorporated (VRTX). BMY differentiates itself through its diverse product portfolio and focus on specialized therapeutic areas.

Who Are BMY's Key Customers?

• Wholesalers and distributors of pharmaceutical products.
• Pharmacies and retailers that dispense prescription drugs.
• Hospitals and clinics that administer treatments to patients.
• Government agencies and healthcare organizations.

Over the past six months, Bristol-Myers Squibb Company insiders filed 15 SEC Form 4 transactions — 6 sales and 9 purchases. On net that is roughly 19K shares disposed (about $2.0M), a signal worth weighing alongside the fundamentals.

Wall Street analysts project Bristol-Myers Squibb Company revenue of about $48.99B for fiscal 2026, with EPS near $6.74. The estimate reflects 15 contributing analysts.

Bristol-Myers Squibb Company has beaten Wall Street's EPS estimate in 8 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 17.2% above estimates on average.

Bristol-Myers Squibb Company's Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 2.81 places it in the grey zone, a middle ground that warrants monitoring.

Return on equity for Bristol-Myers Squibb Company stands at 39.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 8.4%, showing how much profit it generates from its asset base. BMY trades at a trailing price-to-earnings ratio of 15.62, below the Healthcare sector average of ~23x. Its free cash flow yield is 10.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.42 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 6.4%, the inverse of the P/E and a quick read on earnings relative to price.

Bristol-Myers Squibb Company (BMY) Valuation Context

Valued at $134B, BMY is classified as a large-cap stock. Relative to its peer group, BMY's quantitative score of 90/100 is above the peer average of 71/100.

BMY Revenue & Earnings Trend

In Q2 2026, BMY generated $12.97B in top-line revenue, marking a sequential increase of 12.9%. The company recorded net income of $3.32B, with diluted EPS of $1.62. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, BMY averaged $1.14 in diluted EPS.

Company Profile

Bristol-Myers Squibb Company operates in the Drug Manufacturers - General industry within the Healthcare sector. It is headquartered in Princeton, US. The company is led by CEO Christopher S. Boerner. BMY has traded publicly since 1972.

BMY Financials

BMY Latest News

BMY Analyst Consensus

BMY MoonshotScore

Latest Bristol-Myers Squibb Company Analysis

Common Questions About BMY (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources